Literature DB >> 7523477

Tyrosine hydroxylase indicates cell differentiation of catecholamine biosynthesis in neuroendocrine tumors.

K Iwase1, A Nagasaka, I Nagatsu, K Kiuchi, T Nagatsu, H Funahashi, T Tsujimura, A Inagaki, A Nakai, T Kishikawa.   

Abstract

The intracellular localization of tyrosine hydroxylase (TH), which is the rate limiting enzyme in catecholamine (CA) biosynthesis, and its activity in various adrenal and other neuroendocrine tumors was studied. TH was strongly localized in adrenal medulla, pheochromocytoma, and paraganglioma, but was scatteredly expressed in neuroblastoma. TH was not detected in adrenocortical tumors, ganglioneuroma, and other neuroendocrine tumors. Neuron specific enolase (NSE) was found in all neuroendocrine tumors, but Grimelius staining showed only the secreting granules of the tumor cells. TH activity was significantly high in pheochromocytoma and paraganglioma as compared with that in normal adrenal gland, whereas TH activity was low in a neuroblastoma and was undetectable in other tumors. These findings indicate that TH correlates well with the biosynthetic function of CA in the tumor cell and, thus, both the immunostaining of TH and the measurement of its activity in adreno-medullary and related tumors may provide some information about the process of cell differentiation in these tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523477     DOI: 10.1007/BF03348964

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  23 in total

1.  TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS.

Authors:  T NAGATSU; M LEVITT; S UDENFRIEND
Journal:  J Biol Chem       Date:  1964-09       Impact factor: 5.157

2.  Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours.

Authors:  R C Coombes; C Hillyard; P B Greenberg; I MacIntyre
Journal:  Lancet       Date:  1974-06-01       Impact factor: 79.321

3.  Ectopic production of calcitonin.

Authors:  O L Silva; K L Becker; A Primack; J Doppman; R H Snider
Journal:  Lancet       Date:  1973-08-11       Impact factor: 79.321

4.  Maturation of neuroblastoma to ganglioneuroma.

Authors:  K Aterman; E F Schueller
Journal:  Am J Dis Child       Date:  1970-09

5.  Tyrosine hydroxylase activity in blood platelets, plasma and leucocytes.

Authors:  G D'Andrea; K M Welch; B Czarnecki; R Joseph; S R Levine
Journal:  Thromb Res       Date:  1986-12-01       Impact factor: 3.944

6.  Improved reaction buffers for solid-phase enzyme immunoassay without interference by serum factors.

Authors:  K Kato; Y Umeda; F Suzuki; A Kosaka
Journal:  Clin Chim Acta       Date:  1980-03-28       Impact factor: 3.786

7.  Effects of chemical sympathectomy in neonatal and adult mice on C-1300 neuroblastoma tumor growth and catecholamine content.

Authors:  D W Fink; B L Mirkin
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

8.  Detection of tyrosine hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcription-polymerase chain reaction.

Authors:  H Naito; N Kuzumaki; J Uchino; R Kobayashi; T Shikano; Y Ishikawa; S Matsumoto
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

9.  Multiple forms of tyrosine hydroxylase in human neuroblastoma cells: quantitation with isoform-specific antibodies.

Authors:  J W Haycock
Journal:  J Neurochem       Date:  1993-02       Impact factor: 5.372

10.  Highly sensitive assay for tyrosine hydroxylase activity by high-performance liquid chromatography.

Authors:  T Nagatsu; K Oka; T Kato
Journal:  J Chromatogr       Date:  1979-07-21
View more
  8 in total

Review 1.  Ectopic sphenoid sinus pituitary adenoma (ESSPA) with normal anterior pituitary gland: a clinicopathologic and immunophenotypic study of 32 cases with a comprehensive review of the english literature.

Authors:  Lester D R Thompson; Raja R Seethala; Susan Müller
Journal:  Head Neck Pathol       Date:  2012-03-20

2.  Proceedings of the 2017 National Toxicology Program Satellite Symposium.

Authors:  Susan A Elmore; Famke Aeffner; Dinesh S Bangari; Torrie A Crabbs; Stacey Fossey; Shayne C Gad; Wanda M Haschek; Jessica S Hoane; Kyathanahalli Janardhan; Ramesh C Kovi; Gail Pearse; Lyn M Wancket; Erin M Quist
Journal:  Toxicol Pathol       Date:  2017-11-07       Impact factor: 1.902

3.  Primary paraganglioma of the thyroid gland.

Authors:  S Corrado; V Montanini; C De Gaetani; F Borghi; G Papi
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

4.  A comparative immunohistochemical study of spontaneous and chemically induced pheochromocytomas in B6C3F1 mice.

Authors:  Georgette D Hill; Virgilio Pace; Elke Persohn; Christina Bresser; Joseph K Haseman; Arthur S Tischler; Abraham Nyska
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

5.  Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma.

Authors:  Tasnim Ara; Rie Nakata; Michael A Sheard; Hiroyuki Shimada; Ralf Buettner; Susan G Groshen; Lingyun Ji; Hua Yu; Richard Jove; Robert C Seeger; Yves A DeClerck
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

6.  Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumors-gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors.

Authors:  Divya Mamilla; Irena Manukyan; Patricia A Fetsch; Karel Pacak; Markku Miettinen
Journal:  Hum Pathol       Date:  2020-07-12       Impact factor: 3.466

Review 7.  Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma.

Authors:  Annika M A Berends; Graeme Eisenhofer; Lauren Fishbein; Anouk N A V D Horst-Schrivers; Ido P Kema; Thera P Links; Jacques W M Lenders; Michiel N Kerstens
Journal:  Cancers (Basel)       Date:  2019-08-06       Impact factor: 6.639

8.  Therapeutically targeting oncogenic CRCs facilitates induced differentiation of NB by RA and the BET bromodomain inhibitor.

Authors:  Satyanarayana Alleboina; Nour Aljouda; Mellessa Miller; Kevin W Freeman
Journal:  Mol Ther Oncolytics       Date:  2021-09-25       Impact factor: 7.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.